Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

Takeda to distribute Kaketsuken's seasonal influenza vaccine in Japan Japan-based Takeda Pharmaceutical has entered into an agreement for the distribution of Chemo-Sero-Therapeutic Research Institute's (Kaketsuken) seasonal influenza vaccine (Influenza HA Vaccine 'Kaketsuken') in Japan. Drug Research > Drug Delivery > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Omeros' Omidria gets EMA committee positive opinion for cataract and IOL procedures
By PBR Staff Writer
US-based biopharmaceutical firm Omeros has received positive opinion from the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) for Omidria (phenylephrine and ketorolac injection) 1%/0.3%, for use during cataract surgery and other intraocular lens (IOL) replacement procedures.
News
Janssen psoriasis drug Stelara gets CHMP positive opinion to treat adolescents
By PBR Staff Writer
Janssen-Cilag International (Janssen) has received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the use of Stelara (ustekinumab) to treat moderate to severe plaque psoriasis in adolescent patients.
News

Drug Discovery & Development

SignalRx gets STTR grant from NIH to develop dual PI3 kinase/bromodomain inhibitors as anticancer agents
SignalRx Pharmaceuticals, focused on developing more effective oncology drugs though molecular design imparting selective multiple target inhibition, announced that it has received non-dilutive funding to advance the preclinical development of unique small molecule inhibitors designed to inhibit multiple critical cancer targets.
News
Faron, China Medical System to develop traumakine to treat ARDS
By PBR Staff Writer
Finnish biopharmaceutical firm Faron, China Medical Systems (CMS) and A&B have entered into a strategic agreement to develop and commercialize traumakine to treat moderate to severe acute respiratory distress syndrome (ARDS).
News